The Global Stents Market is projected to reach $12.69 billion by 2028, from a value of $8.94 billion in 2022, by registering a CAGR of 6.0% during the forecast period. Rising demand for minimally invasive procedures, a growing geriatric population, and the increasing prevalence of chronic diseases are the major factors propelling the growth of the market. However, high product recalls and stringent approval processes for stents are hampering the market growth. Moreover, advancement in healthcare technology is creating ample opportunities across the globe.
Recent Developments
In Oct 2020, Olympus Corporation launched HANAROSTENT Esophagus TTS self-expanding metal stents (SEMS) made by M.I. Tech and distributed exclusively through Olympus in the U.S. The Through-the-Scope (TTS) esophageal stent, the newest addition to the Olympus self-expanding stent portfolio, helps to achieve luminal patency in a variety of clinical applications and is designed for use in the palliative treatment of esophageal stricture and/or trachea-esophageal fistula caused by malignant tumors.
In July 2020, Biotronik launched its next-generation balloon-expandable cobalt chromium iliac stent system, Dynetic®-35. When compared to leading competitors, the new peripheral stent has up to 14 times greater flexibility and up to 23% higher radial strength.1,2 It is indicated for the treatment of de novo or restenotic atherosclerotic lesions in the iliac arteries and is approved for use in Europe and other markets that recognize CE mark certification.
In June 2020, BD (Becton, Dickinson and Company) acquired Straub Medical AG. This acquisition allows BD to immediately deliver advanced technologies in both atherectomy and thrombectomy and further enhances BDs already strong portfolio of drug-coated, angioplasty and scoring balloons, stents, stent grafts and CTO crossing products for the treatment of PAD and venous disease.
In Oct 2019, Medtronic plc launched the Valiant Navion thoracic stent graft system in Japan for the minimally invasive repair of thoracic descending aortic aneurysms (TAA) and complicated type B aortic dissections (TBAD). The low-profile Valiant Navion system is built to further improve upon the performance of the market-leading Valiant Captivia thoracic stent graft system, which has treated more than 100,000 patients globally, while also broadening patient applicability.
Competitive Landscape
Terumo Corporation, Boston Scientific Corporation, Microport Scientific Corporation, Elixir Medical Corporation, C.R. Bard, Inc., Medtronic plc, B. Braun Melsungen AG, Abbott Laboratories, STENTYS S.A., Biotronik, Olympus Corporation, and BD (Becton, Dickinson and Company) are some of the major players in the global Stents market.
